

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-38. (Canceled).

39. (Currently Amended) A method for promoting angiogenesis in a subject in need thereof comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B according to claim 1.

40. (Currently Amended) A method for treating a disease or condition characterized by the absence of desired angiogenesis in a subject in need thereof comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B according to claim 1.

41. (Original) The method according to claim 40, wherein the disease or condition is selected from the group consisting of: coronary artery disease, wound healing, peripheral vascular disease associated with diabetes, peripheral vascular disease, peripheral artery disease.

42. (Currently Amended) A method for treating or preventing a condition or disease characterized by pathological vascular remodeling in a subject in need thereof comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B according to claim 1.

43. (Original) The method according to claim 42, wherein the disease or condition is selected from the group consisting of: hypertension, restinosis, transplant vasculopathy, arteriosclerosis, ischemia, pulmonary hypertension, asthma, myocardial infarction and

cerebrovascular infarction.

44. (Currently Amended) A method for promoting vascular quiescence in a subject in need thereof comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B according to claim 1.

45. (Original) The method according to claim 44, wherein the subject suffers from a condition selected from the group consisting of: asthma, hypertension, pulmonary hypertension.

46-48. (Canceled).

49. (Currently Amended) A method for reducing neointima formation in a blood vessel in a subject in need thereof comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B according to claim 1.

50. (Currently Amended) A method for inhibiting vascular injury-induced vascular narrowing or occlusion in a subject comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B according to claim 1.

51. (Currently Amended) A method for preventing vascular injury induced ischemia comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B according to claim 1.

52. (Currently Amended) A method for promoting endothelial cell adhesion, spreading and migration comprising the step of contacting the cell with Nogo-B or a fragment thereof that retains a biological activity of Nogo-B.

53. (Original) A method for inhibiting vascular smooth muscle cell migration comprising contacting the cells with Nogo-B or a fragment thereof that retains a biological activity of Nogo-B.

54. (Currently Amended) A method for treating a subject suffering from a vascular injury comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B according to claim 1.